Short-Term Effects of Lovastatin Therapy on Proteinuria of Type 2 Diabetic Nephropathy

Drug Applied Research Center0 个研究点目标入组 30 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•Men with clinically documented T2DN were enrolled. To eliminate potential confounding factors, we only included patients with type 2 diabetes mellitus and proteinuria levels lower than the nephrotic range (i.e., < 3 g/d) whose estimated glomerular filtration rate (eGFR) was higher than 30 mL/min/1.73m2 (as calculated by the Modification of Diet in Renal Disease formula).
•The fasting plasma glucose (FPG) of the participants was controlled by insulin injection and/or administration of oral sulfonylurea. Blood pressure (BP) was maintained at less than 129/79 mm Hg with treatment by angiotensin-converting enzyme inhibitors (ACEI) and/or angiotensin receptor blockers (ARB), with a-blockers and diuretics when needed. All of the patients were under their own regular restricted protein diet (= 0.8 g/kg/d), as prescribed by a nutrition consultant. Any major changes in blood pressure, protein intake, or physical activity during the study period were considered as withdrawal criteria. Exclusion criteria included: the use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) antagonists, fibrates, aspirin, ß-blockers, allopurinol, vitamins, pentoxifylline, fish oil, other antioxidant drugs consumed in the previous three months, active smoking, chronic inflammation (such as diabetic foot, hepatitis, infection, etc.), active coronary artery disease in the previous three months (diagnosed by symptoms and electrocardiography), and poorly controlled diabetes mellitus (Hb-A1c > 7.5%).

发起方

Drug Applied Research Center